MX392410B - Expresión inducida de factor neurotrófico derivado cerebral (bdnf) para tratamiento de enfermedades neuromusculares, neurodegenerativas, autoinmunes, de desarrollo y/o metabólicas. - Google Patents
Expresión inducida de factor neurotrófico derivado cerebral (bdnf) para tratamiento de enfermedades neuromusculares, neurodegenerativas, autoinmunes, de desarrollo y/o metabólicas.Info
- Publication number
- MX392410B MX392410B MX2017009402A MX2017009402A MX392410B MX 392410 B MX392410 B MX 392410B MX 2017009402 A MX2017009402 A MX 2017009402A MX 2017009402 A MX2017009402 A MX 2017009402A MX 392410 B MX392410 B MX 392410B
- Authority
- MX
- Mexico
- Prior art keywords
- disease
- disorders
- syndrome
- developmental
- autoimmune
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
- A61K31/06—Phenols the aromatic ring being substituted by nitro groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Psychology (AREA)
- Obesity (AREA)
- Physical Education & Sports Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562106365P | 2015-01-22 | 2015-01-22 | |
| PCT/US2016/014312 WO2016118741A1 (en) | 2015-01-22 | 2016-01-21 | Induced expression of brain derived neurotrophic factor (bdnf) for treatment of neuromuscular, neurodegenerative, autoimmune, developmental and/or metabolic diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2017009402A MX2017009402A (es) | 2017-12-04 |
| MX392410B true MX392410B (es) | 2025-03-11 |
Family
ID=55310938
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017009402A MX392410B (es) | 2015-01-22 | 2016-01-21 | Expresión inducida de factor neurotrófico derivado cerebral (bdnf) para tratamiento de enfermedades neuromusculares, neurodegenerativas, autoinmunes, de desarrollo y/o metabólicas. |
| MX2022005937A MX2022005937A (es) | 2015-01-22 | 2017-07-18 | Expresion inducida de factor neurotrofico derivado cerebral (bdnf) para tratamiento de enfermedades neuromusculares, neurodegenerativas, autoinmunes, de desarrollo y/o metabolicas. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022005937A MX2022005937A (es) | 2015-01-22 | 2017-07-18 | Expresion inducida de factor neurotrofico derivado cerebral (bdnf) para tratamiento de enfermedades neuromusculares, neurodegenerativas, autoinmunes, de desarrollo y/o metabolicas. |
Country Status (13)
| Country | Link |
|---|---|
| US (6) | US9763896B2 (https=) |
| EP (2) | EP4306167B1 (https=) |
| JP (3) | JP6951976B2 (https=) |
| KR (1) | KR102690198B1 (https=) |
| CN (2) | CN107405315A (https=) |
| AU (2) | AU2016209255B2 (https=) |
| BR (1) | BR112017015721A2 (https=) |
| CA (1) | CA2974092A1 (https=) |
| ES (2) | ES2961334T3 (https=) |
| HK (1) | HK1247101A1 (https=) |
| MX (2) | MX392410B (https=) |
| PT (1) | PT3247340T (https=) |
| WO (1) | WO2016118741A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107405315A (zh) | 2015-01-22 | 2017-11-28 | 米托充制药公司 | 用于治疗神经肌肉、神经变性、自身免疫、发育和/或代谢疾病的脑源性神经营养因子(bdnf)的诱导表达 |
| WO2018129258A1 (en) | 2017-01-06 | 2018-07-12 | Gencia Corporation | Novel phenyl derivatives |
| AU2018215056A1 (en) * | 2017-01-31 | 2019-08-08 | Charles E. Inturrisi | D-methadone and its derivatives for use in the treatment of disorders of the nervous system |
| CA3061201A1 (en) | 2017-06-23 | 2018-12-27 | Enzo Biochem, Inc. | Sphingosine pathway modulating compounds for the treatment of cancers |
| US10660879B2 (en) | 2017-06-23 | 2020-05-26 | Enzo Biochem, Inc. | Sphingosine pathway modulating compounds for the treatment of cancers |
| US20210393621A1 (en) | 2018-10-26 | 2021-12-23 | The Research Foundation For The State University Of New York | Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia |
| EP4223307A4 (en) * | 2020-09-29 | 2024-07-24 | Cefo Co., Ltd. | COMPOSITION FOR THE PREVENTION OR TREATMENT OF A NEUROPSYCHOLOGICAL DISEASE, COMPRISING MANF |
| WO2023205625A2 (en) * | 2022-04-18 | 2023-10-26 | Mitochon Pharmaceuticals, Inc. | 2,4 dnp and prodrugs thereof for treatment of pulmonary and autoimmune diseases |
| WO2025051360A1 (en) * | 2023-09-06 | 2025-03-13 | Instituto de Medicina Molecular João Lobo Antunes | Trkb-t1 agonist for the treatment of absence seizure and/or comorbidities |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6664297B1 (en) * | 2000-10-18 | 2003-12-16 | Universidade Federal Do Rio De Janeiro | Methods for inhibition and dissolution of amyloidoses by administration of compositions comprising 2,4-dinitrophenol |
| US7135575B2 (en) * | 2003-03-03 | 2006-11-14 | Array Biopharma, Inc. | P38 inhibitors and methods of use thereof |
| EP1764095A1 (en) * | 2005-09-20 | 2007-03-21 | Revotar Biopharmaceuticals AG | Novel nitrocatechol derivatives having selectin ligand activity |
| US20100130597A1 (en) | 2007-07-06 | 2010-05-27 | The United State Of America, As Represented By The Secretary Of The Dept Of Health And Human Service | Dna-pkcs modulates energy regulation and brain function |
| WO2015031756A1 (en) * | 2013-08-30 | 2015-03-05 | Yale University | Novel 2,4-dinitrophenol formulations and methods using same |
| CN107405315A (zh) * | 2015-01-22 | 2017-11-28 | 米托充制药公司 | 用于治疗神经肌肉、神经变性、自身免疫、发育和/或代谢疾病的脑源性神经营养因子(bdnf)的诱导表达 |
-
2016
- 2016-01-21 CN CN201680017379.4A patent/CN107405315A/zh active Pending
- 2016-01-21 CA CA2974092A patent/CA2974092A1/en active Pending
- 2016-01-21 CN CN202211548767.9A patent/CN116617195A/zh active Pending
- 2016-01-21 EP EP23188878.5A patent/EP4306167B1/en active Active
- 2016-01-21 AU AU2016209255A patent/AU2016209255B2/en active Active
- 2016-01-21 ES ES16703409T patent/ES2961334T3/es active Active
- 2016-01-21 ES ES23188878T patent/ES3057870T3/es active Active
- 2016-01-21 EP EP16703409.9A patent/EP3247340B1/en active Active
- 2016-01-21 HK HK18106712.4A patent/HK1247101A1/zh unknown
- 2016-01-21 WO PCT/US2016/014312 patent/WO2016118741A1/en not_active Ceased
- 2016-01-21 US US15/002,531 patent/US9763896B2/en active Active
- 2016-01-21 PT PT167034099T patent/PT3247340T/pt unknown
- 2016-01-21 BR BR112017015721A patent/BR112017015721A2/pt not_active Application Discontinuation
- 2016-01-21 KR KR1020177023034A patent/KR102690198B1/ko active Active
- 2016-01-21 MX MX2017009402A patent/MX392410B/es unknown
- 2016-01-21 JP JP2017539363A patent/JP6951976B2/ja active Active
- 2016-11-21 US US15/357,412 patent/US9974755B2/en active Active
-
2017
- 2017-07-18 MX MX2022005937A patent/MX2022005937A/es unknown
- 2017-09-18 US US15/707,239 patent/US10220006B2/en active Active
-
2019
- 2019-01-17 US US16/250,470 patent/US10864173B2/en active Active
-
2020
- 2020-11-09 US US17/093,193 patent/US11717497B2/en active Active
-
2021
- 2021-03-01 JP JP2021031635A patent/JP7440092B2/ja active Active
- 2021-09-27 AU AU2021240120A patent/AU2021240120A1/en not_active Abandoned
-
2022
- 2022-10-03 JP JP2022159466A patent/JP2022173519A/ja active Pending
-
2023
- 2023-06-16 US US18/336,440 patent/US20240156750A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022005937A (es) | Expresion inducida de factor neurotrofico derivado cerebral (bdnf) para tratamiento de enfermedades neuromusculares, neurodegenerativas, autoinmunes, de desarrollo y/o metabolicas. | |
| PH12018502336A1 (en) | Benzazepine derivative, preparation method , pharmaceutical composition and use thereof | |
| MX386838B (es) | Inhibidores biciclo[1.1.1]pentano de la cinasa de cremallera de leucina dual (dlk) para el tratamiento de enfermedades. | |
| GEP20237483B (en) | Condensed imidazole derivatives substituted by tertiary hydroxy groups as pi3k-gamma inhibitors | |
| MX2019002444A (es) | Inhibidores de cinasa de cremallera de leucina dual (dlk) para el tratamiento de enfermedades. | |
| MX2020002884A (es) | Método y composición neuroprotectora mejorada para tratar afecciones neurológicas. | |
| EP4414037A3 (en) | Morphinan derivatives for the treatment of opioid delta receptor agonist-related diseases | |
| MY189740A (en) | Butylphthalide-telmisartan heterocomplex, preparation method and application thereof | |
| PH12018500430A1 (en) | Brain-penetrant chromone oxime derivative for the therapy of levodopa-induced dyskinesia | |
| NZ709399A (en) | Method of treatment of hypoxia inducible factor (hif)-related conditions | |
| EP4233871A3 (en) | Inhibiting the transient receptor potential a1 ion channel | |
| WO2015013187A8 (en) | Ppar-sparing compounds for the treatment of metabolic diseases | |
| Khatoon et al. | The role of natural products in Alzheimer's and Parkinson's disease | |
| MX2020013692A (es) | Compuestos de pirazol e imidazol para la inhibicion de il-17 y rorgamma. | |
| CA3148794A1 (en) | 4-amino-quinolines/-quinazolines that bind to tdp-43 for the treatment of amyotrophic lateral sclerosis and related disorders | |
| WO2016005962A3 (en) | Stable liquid formulations of cyclophosphamide and processes | |
| BR112021019110A2 (pt) | Compostos e composições farmacêuticas dos mesmos para o tratamento de distúrbios inflamatórios | |
| EP4009949A4 (en) | OLFACTORY DELIVERY OF THERAPEUTIC COMPOUNDS TO THE CENTRAL NERVOUS SYSTEM | |
| MX2023008839A (es) | Composicion de liberacion tardia de linaclotida para uso en el tratamiento de trastornos gastrointestinales. | |
| BR112019000314A2 (pt) | derivados de etinila | |
| BR112018074579A2 (pt) | botão para um dispositivo de administração de fármaco e método para montar um botão para um dispositivo de administração de fármaco | |
| WO2016059269A8 (es) | Compuestos derivados de acrilato de 3-alouilamino-1h- indolilo y su uso en el tratamiento de enfermedades neurodegenerativas | |
| HK1244680A1 (zh) | 用於靜脈內施用反丁烯二酸酯以治療神經疾病的方法和組合物 | |
| YIN | Effects of protocatechuic acid on expression of D2DR, iNOS, and TH in striatum and midbrain of Parkinson's disease model mice | |
| MX2019006169A (es) | Derivados sililados de resveratrol y su uso en enfermedades neurodegenerativas, neurologicas o inflamatorias. |